Tachykinin Isolation: From Frog Skin to Anti-Nausea Drugs

Tachykinin isolation refers to the extraction and purification of a family of short signaling peptides from animal tissues, venoms, and cell cultures. These peptides share a common chemical tail that makes them active in the nervous system, the gut, and the immune system, but getting them out of biological material in pure form has been a persistent technical challenge since researchers first detected their activity in the 1930s. The story of how scientists learned to isolate tachykinins tracks surprisingly closely with the development of modern biochemistry itself, from crude tissue extracts tested on strips of intestinal muscle to nanoscale mass spectrometry of single insect organs.

The First Pure Substance P

The founding member of the tachykinin family, substance P, was noticed as an unnamed “something” in horse brain and gut extracts as early as 1931. Researchers knew the extract made smooth muscle contract and lowered blood pressure, but actually purifying the active molecule took decades. The breakthrough came when a team working with bovine hypothalamic tissue used a combination of gel filtration, ion-exchange chromatography, and high-voltage paper electrophoresis to isolate a single pure peptide. That peptide turned out to be an eleven-amino-acid chain. Biological testing confirmed it was indistinguishable from the mysterious substance P: it contracted guinea pig intestinal tissue, contracted rat intestinal tissue, and lowered blood pressure. This was considered the first complete purification of substance P.¹

The significance here was not just identifying a molecule. It was proving that a biologically active peptide could be chased through increasingly fine separation steps until it emerged as a single, testable compound. Each step in the purification acted as a sieve: gel filtration separated molecules by size, ion-exchange chromatography separated them by electrical charge, and paper electrophoresis provided a final confirmation that only one compound remained. The amino acid composition matched an eleven-residue peptide, and the biological activity matched every known behavior of substance P.²

Frog Skin and the Discovery That Tachykinins Are Everywhere

While neurochemists were working to purify substance P from mammalian brains, pharmacologists studying amphibian skin stumbled onto a parallel universe of related peptides. The skin of the South American frog Physalaemus fuscumaculatus yielded physalaemin, a peptide that shared substance P’s ability to contract smooth muscle and drop blood pressure but had a slightly different amino acid sequence.³ The African frog Kassina senegalensis contributed kassinin, a twelve-amino-acid tachykinin extracted from methanol-treated skin.⁴ Kassinin was then submitted to parallel bioassays alongside physalaemin, eledoisin (from octopus salivary glands), and substance P, establishing that all these peptides belonged to one big family defined by their shared C-terminal sequence motif.⁵

These amphibian discoveries were crucial for a reason that goes beyond cataloging new peptides. Frog skin produces tachykinins in vastly larger quantities than mammalian brain tissue, which made them far easier to isolate and sequence. Physalaemin and kassinin effectively served as abundant, accessible templates that helped researchers recognize what the tachykinin signature looked like at the molecular level. Once that signature was defined, it became much easier to hunt for new family members in harder-to-access mammalian tissues.

Mammalian Variants Beyond Substance P

With improved separation technology in the 1980s, researchers began finding that substance P was not alone in mammalian nervous tissue. Porcine spinal cord and brain yielded neurokinin A, neurokinin B, and neuropeptide K, considerably extending the roster of tachykinin peptides in the mammalian nervous system.⁶ The pig was the workhorse species for these isolations partly because porcine tissue was available in bulk from slaughterhouses, and partly because pig neurobiology is reasonably close to human neurobiology. Each new peptide had to be separated from a complex mixture of hundreds of other neuroactive substances, then tested on smooth-muscle preparations and receptor assays to confirm it was genuinely a tachykinin rather than a fragment or an artifact.

The discovery of multiple mammalian tachykinins raised an immediate question: did they all do the same thing, or did each have a specialized job? Answering that question depended on having pure peptides to test, which meant isolation quality mattered enormously. Even small contaminants could confuse a bioassay, since the nervous system contains dozens of peptides that act on overlapping targets.

Why Isolating Tachykinins Is Technically Difficult

One of the biggest obstacles to tachykinin isolation is that these peptides degrade with alarming speed once they leave the cell. When synthetic substance P was added to guinea pig blood plasma at body temperature, it vanished almost entirely within 30 seconds as measured by immunoassay. Neurokinin A and neuropeptide K were comparatively tougher, declining only modestly over 20 minutes.⁷ This means that the moment you homogenize a piece of brain tissue, a cascade of enzymes starts chewing up the very molecules you are trying to capture. Early researchers learned the hard way that slow or gentle extraction methods gave them nothing.

The standard countermeasure is to work fast and cold, often dropping tissue immediately into boiling acid or acidified methanol to denature the enzymes before they can attack the peptides. This is effective but destructive to the tissue structure, which means you sacrifice the ability to see where in the tissue the peptide was located. It is a recurring trade-off in peptide biochemistry: the conditions that preserve a peptide’s integrity destroy the spatial information you might want about it.

Modern Purification Approaches

By the late 1990s, the toolkit for tachykinin isolation had expanded well beyond the gel filtration and paper electrophoresis of the early days. A revealing example comes from work on the desert locust. Researchers extracted a hundred locust midguts in acidified methanol, then passed the extract through three successive high-performance liquid chromatography (HPLC) columns to obtain a pure peptide. A tachykinin-specific immunoassay tracked the peptide through each step so they always knew which fraction contained the target. After each purification round, the purity was checked by one form of mass spectrometry, and the final sequence was determined by a different, more precise form of mass spectrometry. Automated chemical sequencing and synthesis of the candidate peptide confirmed the result.⁸

This workflow illustrates how modern isolation integrates multiple technologies. HPLC does the heavy lifting of physical separation. Immunoassays act as a biological compass, telling the researcher which fraction to keep. Mass spectrometry provides molecular identity without consuming the entire sample. And chemical synthesis closes the loop: if you build the peptide from scratch according to your proposed sequence and it behaves identically to the natural one, your identification is confirmed.

Immunoaffinity purification offers another route. By coupling a monoclonal antibody against substance P to a solid support, researchers could selectively fish the peptide out of complex mixtures like cell-culture supernatants. This approach was used to demonstrate that certain immune cells (macrophages) produce substance P on their own, a finding with implications for how the nervous and immune systems talk to each other.⁹

Insect Tachykinins and What They Reveal

Insects have turned out to be surprisingly rich sources of tachykinin-related peptides. From a thousand brains of the Madeira cockroach, researchers isolated seven distinct tachykinin-related peptides, sequenced them by chemical degradation, and confirmed six of the seven by mass spectrometry and chemical synthesis. These peptides shared a common C-terminal motif but varied at the other end, and the pattern of variation suggested tissue-specific expression of different forms.¹⁰

The insect work matters for two reasons. First, insects are vastly easier to rear in large numbers than mammals, providing enough starting material for detailed biochemical analysis. Second, insect tachykinins are different enough from mammalian ones that comparing the two families reveals which parts of the molecule are ancient and essential and which parts have drifted over hundreds of millions of years of evolution. The C-terminal end, which determines receptor binding, is extremely well conserved. The N-terminal end varies freely. That pattern tells you where the business end of the molecule is.

How One Gene Makes Multiple Tachykinins

A pivotal finding in tachykinin biology came not from isolating peptides at all, but from cloning the gene that encodes them. Researchers discovered that a single preprotachykinin gene in mammals can produce two distinct messenger RNA molecules through alternative RNA splicing. One version encodes only substance P, while the other encodes both substance P and substance K (now usually called neurokinin A).¹¹ This explained a longstanding puzzle: why certain tissues contained both peptides while others contained only substance P.

The story gets more complicated with a second tachykinin gene. Analysis across mammals, birds, and reptiles identified 35 different precursor forms for the tachykinin 3 gene (which encodes neurokinin B). In humans alone, nine additional alternatively spliced messenger RNA forms were found, producing three different precursor proteins. Despite all this molecular creativity, no entirely new tachykinin peptide emerged from the extra splicing.¹² The genetic machinery generates enormous diversity at the precursor level, but the final active peptides are trimmed down to a conserved set. For isolation work, this means the same peptide can come from precursors of different sizes depending on the tissue, which complicates identification if you are tracking the larger precursor rather than the mature product.

Three Receptors and Why Isolation Purity Matters

Mammals have three main tachykinin receptors, called NK1, NK2, and NK3. Substance P preferentially activates NK1, neurokinin A prefers NK2, and neurokinin B prefers NK3. This receptor selectivity was confirmed using cell lines engineered to express each receptor individually: substance P, neurokinin A, and neurokinin B each triggered the matching receptor most potently, consistent with results from earlier binding studies.¹³

The existence of three receptors with overlapping but distinct preferences is precisely why isolation purity is so important. If your “pure” substance P preparation is contaminated with even a trace of neurokinin A, your bioassay will show activity at NK2 receptors that substance P alone would not produce, and you will draw the wrong conclusion about which receptor substance P actually targets. Many of the early disagreements in the tachykinin literature about receptor selectivity trace back to impure preparations.

What Isolated Tachykinins Taught Us About Pain

Substance P is an eleven-amino-acid peptide that preferentially activates the NK1 receptor and transmits pain signals from peripheral nerves to the spinal cord and brainstem.¹⁴ In conditions of persistent pain, the NK1 receptor gets upregulated in a widespread, non-localized pattern across the spinal cord’s dorsal horn, which may contribute to the way chronic pain seems to “spread” beyond the original injury site.¹⁵

A particularly striking experiment demonstrated the practical importance of this pathway. When spinal neurons expressing the substance P receptor were selectively destroyed using a targeted toxin, animals showed reduced sensitivity to both heat and mechanical stimulation in models of chronic neuropathic and inflammatory pain. This identified those neurons as a potential therapeutic target and showed that a relatively small population of cells in the spinal cord plays a disproportionately large role in maintaining chronic pain.¹⁶ None of this work would have been possible without high-quality isolated substance P to use as a tool compound in the first place.

Tachykinins in the Gut

Pain signaling is the most famous role of tachykinins, but the gut may be where they do the most continuous daily work. Tachykinins released from both intrinsic gut neurons and incoming sensory neurons influence muscle and nerve throughout the digestive tract by acting on all three receptor types. Their most prominent effect is stimulating movement, which occurs in virtually every region and layer of the mammalian gut. This involves direct activation of muscle cells through NK1 and NK2 receptors, plus activation of excitatory nerve pathways through NK3 and NK1 receptors. Tachykinins can also inhibit motility by triggering inhibitory neural circuits or by interrupting excitatory relays.¹⁷

More specific findings showed that NK1 receptors on the circular muscle of the colon may mediate the large propulsive contractions of the colon, while NK3 receptors on certain neurons mediate the equivalent contractions in the small intestine.¹⁸ These distinctions matter for drug development: a drug that blocks NK1 receptors will affect colon motility differently than one that blocks NK3, which means isolation and receptor characterization are not just academic exercises but have direct therapeutic relevance.

Tachykinins in Venom

Some of the most unexpected tachykinin isolations have come from animal venoms. Octopus venoms contain tachykinin peptides that, despite originating from an invertebrate, structurally resemble vertebrate tachykinins more than they resemble the conventional invertebrate forms. Testing three variant octopus tachykinins on both invertebrate and vertebrate muscle preparations showed that their relative potencies were consistent across both tissue types, suggesting the peptide-receptor interaction is more universal than previously assumed. The most potent variant was also the most electrically charged and structurally stable.¹⁹

Stonefish venom presents a different scenario. Rather than containing tachykinins directly, stonefish venom appears to trigger the release of the victim’s own endogenous tachykinins. Venom injected into guinea pigs caused dose-dependent constriction of the airways, and this effect was significantly reduced by an NK1 receptor blocker. The interpretation is that the venom contains a component that stimulates endogenous tachykinin release, which then acts on NK1 receptors to cause bronchoconstriction.²⁰ From an isolation standpoint, the distinction matters: isolating a tachykinin directly from venom is a different problem than isolating evidence that venom causes tachykinin release in the victim.

Post-Translational Modifications and Hidden Complexity

Even after a tachykinin is isolated and sequenced, the story is not always complete. Hemokinin-1, a relatively recently discovered mammalian tachykinin, was identified in mouse tissue as an amidated ten-amino-acid peptide present in both brain and peripheral organs. But mass spectrometry revealed an additional form carrying an acetyl group attached after the peptide was made, and this modification appeared exclusively in the brain.²¹ This brain-specific chemical tag could alter how the peptide behaves, how long it lasts, or which receptor it prefers. It also means that isolating hemokinin-1 from brain tissue and isolating it from, say, spleen tissue may give you subtly different molecules even though the underlying gene sequence is the same.

Post-translational modifications like acetylation create a challenge for any isolation workflow that relies on a single antibody or a single expected mass. If your immunoassay is calibrated to the unmodified form, the modified version may slip through undetected. This is one reason modern isolation protocols increasingly rely on unbiased mass spectrometry scans rather than targeted assays alone.

Evolutionary Threads Across Species

Tachykinin genes have been traced across vertebrates from fish to mammals. In zebrafish, phylogenetic analysis showed that fish tachykinin 3 genes and mammalian neurokinin genes descend from a common ancestor. An intriguing twist: the fish gene encodes two putative tachykinin peptides, while the mammalian equivalent encodes only one. The second fish peptide, dubbed neurokinin F, is unique to fish but conserved across multiple fish species, suggesting it serves a function that mammals have either lost or reassigned to a different signaling system.²² For researchers interested in isolating tachykinins from non-model organisms, this means you cannot assume the mammalian playbook applies. A fish or reptile may have family members that simply do not exist in mice or humans.

From Isolated Peptides to Anti-Nausea Drugs

Perhaps the most tangible payoff from decades of tachykinin isolation work is the development of aprepitant, the first NK1 receptor antagonist approved for preventing chemotherapy-induced nausea and vomiting. Aprepitant works in the brain’s vomiting centers by blocking NK1 receptors so that substance P, released as an unwanted side effect of chemotherapy, cannot activate them.²³ The drug would have been impossible to design without the prior isolation and characterization of substance P, the cloning and expression of the NK1 receptor, and the structure-activity work that told chemists which part of the peptide to mimic or block.

Aprepitant’s existence quietly validates every step of the isolation pipeline, from the early bovine hypothalamus extracts to the receptor-binding assays on engineered cell lines. Each advance in purity and identification fed into the next stage of pharmaceutical development. It is a useful reminder that the painstaking, unglamorous work of extracting tiny amounts of peptide from tissue homogenates can eventually produce a drug that changes quality of life for cancer patients around the world.